Daily Brief Health Care: INVO BioScience , Medpace Holdings Inc and more

• INVO Fertility, Inc. is a healthcare services and technology company focused on the fertility marketplace, expanding access to assisted reproductive technology (ART) care.
• Proprietary INVOcell® device enables in vivo fertilization and early embryo development, demonstrating equivalent pregnancy success and live birth rates as IVF.
• Auditors’ reports for December 31, 2025 and 2024 contain an explanatory paragraph relating to the ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Medpace Holdings, Inc. reported financial results for the second quarter of 2026, highlighting revenue growth, improving net bookings, and ongoing shifts in clinical trial composition and backlog management.
• Revenue for the quarter reached $707.3 million, representing a 17.2% increase year-over-year, while year-to-date revenue totaled $1.41 billion, up 21.7%.
• EBITDA rose 17.6% to $153.4 million in the quarter with a margin largely stable at 21.7%, and net income increased by 34.5% to $121.4 million, supported by a lower effective tax rate and higher interest income.